# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation....
Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary art...
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...
Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.